Genetically modified cell and process for use of said cell
AssigneePurac Biochem B.V.
InventorsNick Johannes Petrus Wierckx, Tom Daniel Elink Schuurman, Sipko Maarten Kuijper, Harald Johan Ruijssenaars
Life of this patent
Estimating the term…
Abstract
The present invention relates to the field of biotransformation of furanic compounds. More particular the present invention relates to novel genetically modified cells with improved characteristics for biocatalytic transformation of furanic compounds and a vector suitable for the genetic modification of a host cell. Further aspects of the invention are aimed at processes for biotransformation of 5-(hydroxymethyl)furan-2-carboxylic acid (HMF-acid) and its precursors with the use of the cell according to the invention.
Claims22
An isolated cell that is genetically modified by the introduction of a first polynucleotide sequence coding for a polypeptide having 5-(hydroxymethyl)furan-2-carboxylic acid (HMF-acid) transport capabilities, wherein the first polynucleotide sequence has at least 95% sequence identity with SEQ ID NO:
- 7;
- and a second polynucleotide sequence coding for a polypeptide having HMF-acid oxidoreductase activity, wherein the polypeptide having HMF-acid oxidoreductase activity comprises an amino acid sequence having at least 95% sequence identity with at least one of SEQ ID NO:
- 5 and 6.
A vector comprising a first polynucleotide sequence coding for a polypeptide having 5-(hydroxymethyl)furan-2-carboxylic acid (HMF-acid) transport capabilities, wherein the first polynucleotide sequence has at least 95% sequence identity with SEQ ID NO:
- 7;
- and a second polynucleotide sequence coding for a polypeptide having HMF-acid oxidoreductase activity, wherein the polypeptide having HMF-acid oxidoreductase activity comprises an amino acid sequence having at least 95% sequence identity with at least one of SEQ ID NO:
- 5 and 6.
Dependencies are inferred from the claim text.